Singapore, June 12, 2024 – Update on Detection of Existing Influenza A Variant
Credo Diagnostics Biomedical Pte. Ltd. is committed to the post-market monitoring of the reliability of our assays. We have performed nucleotide analysis using the BLASTn method comparing primers and probes of the assays involving influenza A virus detection to all sequences listed in NCBI Virus and GISAID up till June 9th, 2024.
We are pleased to announce that the VitaPCR™ system is capable of detecting the influenza A subtypes and variants as listed in the table below.
- Subtypes: H1N1, H1N2, H3N2, H5N1, H5N2, H3N8, H5N6, H7N9, H7N3, H9N2, H10N5
- Variants: H1N1pdm09 variant and H3N2 variants: clade 3C.2a1b.2a.2 and clade 3C.2a1b.1a
Our analysis has confirmed that the performance of our influenza detection assays* are not
impacted by the variants.
*The influenza detection assays include:
– VitaPCR™ Influenza/SARS-CoV-2 (Flu/SC2) Assay (PCRAE0128)
– VitaPCR™ Flu A&B Assay (PCRAE0103)
– VitaPCR™ Flu / RSV Assay (PCRAE0106)
For more information, contact us at service@credodxbiomed.com.
